2-Bromohexadecanoic acid
(Synonyms: 2-溴棕榈酸) 目录号 : GC19850
2-Bromohexadecanoic acid是一种脂质代谢的非选择性抑制剂，是蛋白质S-棕榈酰化的通用抑制剂。
Cas No.:18263-25-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
2-Bromohexadecanoic acid is a non-selective inhibitor of lipid metabolism and a general inhibitor of protein S-palmitoylation[1]. 2-Bromohexadecanoic acid directly and irreversibly inhibits the palmitoyltransferase activity of all DHHC (Asp-His-His-Cys) proteins[2]. 2-Bromohexadecanoic acid strongly inhibits the replication of mouse hepatitis virus (MHV-A59), mainly by specifically destroying lipid droplets[3].
In vitro, 2-Bromohexadecanoic acid (50μM) pretreatment of Hela cells for 1h significantly inhibited TNFα+CHX-induced cell pyroptosis, but did not inhibit cell apoptosis, and reduced lactate dehydrogenase release and PI-positive cells[4]. 2-Bromohexadecanoic acid (75-150μM) treatment of HepG2 cells significantly reduced palmitate (PA)-induced cancer stem cell (CSC) sphere formation, but did not affect cell viability[5]. Treatment of CHO-K1 cells co-expressing diacylated GAP-43-YFP and GalNAc-T-CFP with 2-Bromohexadecanoic acid (25, 50, 150μM) significantly reduced the TGN-membrane association of growth-associated protein-43 (GAP-43)[6].
References:
[1] Davda D, El Azzouny M A, Tom C T M B, et al. Profiling targets of the irreversible palmitoylation inhibitor 2-bromopalmitate[J]. ACS chemical biology, 2013, 8(9): 1912-1917.
[2] Yu W, Yang K, Zhao M, et al. Design, synthesis and biological activity evaluation of novel covalent S-acylation inhibitors[J]. Molecular Diversity, 2024, 28(3): 1073-1092.
[3] Liu D, Cruz-cosme R, Leibowitz J, et al. Uncovering the Vital Role of Lipid Droplets in Coronavirus Replication: A Novel Insight Arising from the Biological Activity of 2-Bromopalmitate[J]. bioRxiv, 2023: 2023.06. 29.547086.
[4] Hu L, Chen M, Chen X, et al. Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate[J]. Cell death & disease, 2020, 11(4): 281.
[5] Chong L W, Tsai C L, Yang K C, et al. Targeting protein palmitoylation decreases palmitate-induced sphere formation of human liver cancer cells[J]. Molecular Medicine Reports, 2020, 22(2): 939-947.
[6] Pedro M P, Vilcaes A A, Tomatis V M, et al. 2-Bromopalmitate reduces protein deacylation by inhibition of acyl-protein thioesterase enzymatic activities[J]. PloS one, 2013, 8(10): e75232.
2-Bromohexadecanoic acid是一种脂质代谢的非选择性抑制剂，是蛋白质S-棕榈酰化的通用抑制剂[1]。2-Bromohexadecanoic acid直接且不可逆地抑制所有DHHC（Asp-His-His-Cys）蛋白的棕榈酰转移酶活性[2]。2-Bromohexadecanoic acid强烈抑制鼠肝炎病毒（MHV-A59）复制，主要作用是特异性破坏脂滴[3]。
在体外，2-Bromohexadecanoic acid（50μM）预处理Hela细胞1h，显著抑制了TNFα+CHX诱导的细胞焦亡，但不抑制细胞凋亡，减少了乳酸脱氢酶释放和PI阳性细胞[4]。2-Bromohexadecanoic acid（75-150μM）处理HepG2细胞，显著减少了棕榈酸酯（PA）诱导的癌症干细胞（CSC）球体形成，但不影响细胞活力[5]。2-Bromohexadecanoic acid（25、50、150μM）处理共表达二酰化 GAP-43-YFP和GalNAc-T-CFP的CHO-K1细胞，显著减少了生长相关蛋白-43（GAP-43）的TGN-膜关联性[6]。
| Cell experiment [1]: | |
Cell lines | Hela cells |
Preparation Method | Hela cells were pre-incubated with 2-Bromohexadecanoic acid (50μM) for 1h and then treated with TNFα (20ng/mL)+Cycloheximide(CHX) (10μg/mL) for the indicated time (0, 3, 6, 9, 12h), followed by Hoechst 33342/PI double staining, fluorescence microscopy images were taken, and the proportion of PI-positive cells was determined using Image J software. The culture supernatant was collected to measure the percentage of LDH release. |
Reaction Conditions | 50μM; 1h |
Applications | Cells pre-incubated with palmitoylation inhibitor 2-Bromohexadecanoic acid, decreased the LDH release and the PI positive cells after TNFα+CHX treatment. |
References: [1]Hu L, Chen M, Chen X, et al. Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate[J]. Cell death & disease, 2020, 11(4): 281. | |
| Cas No. | 18263-25-7 | SDF | |
| 别名 | 2-溴棕榈酸 | ||
| 分子式 | CH3(CH2)13CH(Br)CO2H | 分子量 | 335.32 |
| 溶解度 | Methanol : 100mg/ml(298.2226） | 储存条件 | Store at RT , protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9822 mL | 14.9111 mL | 29.8223 mL |
| 5 mM | 0.5964 mL | 2.9822 mL | 5.9645 mL |
| 10 mM | 0.2982 mL | 1.4911 mL | 2.9822 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet